MarketInOut Stock Screener Log In | Sign Up

Arbutus Biopharma Corp

IEX • Healthcare • Biotechnology • Quote as of 11/17/2026 15:59
Arbutus Biopharma Corp stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeIEX
Market Capitalization620.84 mln
Float153 mln
Earnings Date03/04/2027

EPS

1.12
Decent

P / E

3.63
Deeply undervalued

Piotroski F-Score

6 / 9
Solid

Beneish M-Score

4.53
Highly suspicious

1-Year Forecast

5.34
Strong upside

Relative Strength

91 / 100
Top performer

Business Description

Arbutus Biopharma is a clinical-stage company based in Warminster, Pennsylvania, focused on developing new treatments for chronic Hepatitis B. Its two lead drug candidates work in complementary ways ? one reduces harmful viral proteins in the body, while the other helps the immune system recognize and fight the infection. The company also holds a licensing agreement with Alnylam Pharmaceuticals to use their drug delivery technology in developing its products.

Key Fundamentals

EPS1.12
P/E3.63
ROE145
RPS0.93
ROIC122
ROA102
Interest Cover2,273
EBITDA, mln220
EV / EBITDA2.01
EV / EBIT2.01
Revenue, mln181
EV / Revenue2.44

Quote Details

Last 4.06
Change 0.01 (0.25%)
Open 4.04
Volume 1,932,318
Turnover 7,845,211
Average Volume 2,085,880

Financial Ratios

Pre-Tax Profit Margin121
Leverage Ratio3.96
Current Ratio1.40
Price / Book9.09
Price / Tangible Book9.09
Price / Cash Flow3.64
Price / Free Cash Flow3.57
Debt / Equity0.04
Price / Sales4.22
PEG Ratio0.16

Financial Strength

Altman Z-Score0.07
Piotroski F-Score 6 / 9
Beneish M-Score4.53
Price to Graham Number1.19
1-Year Target Price5.34
Short Ratio4.40
Short % of Float14.78

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 6.28% 97 / 100   
1 Month -4.02% 43 / 100   
2 Months -11.55% 37 / 100   
6 Months -3.33% 43 / 100   
1 Year -10.18% 37 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog